Voriconazole pharmacokinetics and pharmacodynamics in children.
暂无分享,去创建一个
[1] W. Haefeli,et al. CYP2C19 Genotype Is a Major Factor Contributing to the Highly Variable Pharmacokinetics of Voriconazole , 2009, Journal of clinical pharmacology.
[2] Mats O. Karlsson,et al. Population Pharmacokinetic Analysis of Voriconazole Plasma Concentration Data from Pediatric Studies , 2008, Antimicrobial Agents and Chemotherapy.
[3] S. Coffin,et al. Pediatric Antifungal Utilization: New Drugs, New Trends , 2008, The Pediatric infectious disease journal.
[4] J. Perfect,et al. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. , 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[5] D. Andes,et al. Therapeutic drug monitoring of antifungals: pharmacokinetic and pharmacodynamic considerations. , 2008, Therapeutic drug monitoring.
[6] Thierry Buclin,et al. Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes. , 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[7] R. Drew,et al. Antifungal serum concentration monitoring: an update. , 2007, The Journal of antimicrobial chemotherapy.
[8] D. Andes,et al. Voriconazole Therapeutic Drug Monitoring , 2006, Antimicrobial Agents and Chemotherapy.
[9] M. Ghannoum,et al. Correlation of MIC with Outcome for Candida Species Tested against Voriconazole: Analysis and Proposal for Interpretive Breakpoints , 2006, Journal of Clinical Microbiology.
[10] N. Wood,et al. Investigation of the Potential Relationships Between Plasma Voriconazole Concentrations and Visual Adverse Events or Liver Function Test Abnormalities , 2006, Journal of clinical pharmacology.
[11] M. Karlsson,et al. Pharmacokinetics and Safety of Intravenous Voriconazole in Children after Single- or Multiple-Dose Administration , 2004, Antimicrobial Agents and Chemotherapy.
[12] N. Wood,et al. Effect of food on the pharmacokinetics of multiple-dose oral voriconazole. , 2003, British journal of clinical pharmacology.
[13] D. Andes,et al. In Vivo Pharmacokinetics and Pharmacodynamics of a New Triazole, Voriconazole, in a Murine Candidiasis Model , 2003, Antimicrobial Agents and Chemotherapy.
[14] Richard Sylvester,et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. , 2002, The New England journal of medicine.
[15] E. Thiel,et al. Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis. , 2002, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[16] M. O. Karlsson,et al. The importance of modeling interoccasion variability in population pharmacokinetic analyses , 1993, Journal of Pharmacokinetics and Biopharmaceutics.
[17] Lauren A. Destino,et al. Annals of Clinical Microbiology and Antimicrobials Open Access Severe Osteomyelitis Caused by Myceliophthora Thermophila after a Pitchfork Injury , 2022 .